Monitor for updates on the End-of-Phase 2 meeting with the FDA in mid-2026, as this will be a critical milestone for the Phase 3 program. The positive CMC feedback reduces regulatory risk and supports the company's timeline.
Price Chart
Executive Summary
Alterity Therapeutics announced positive FDA feedback on the chemistry, manufacturing, and control (CMC) elements of its planned Phase 3 program for ATH434 in Multiple System Atrophy. This follows a prior Type C meeting and supports readiness for Phase 3 initiation. Additionally, a substantial shareholder increased their holding in the company.
Key Facts
- Received positive FDA feedback on CMC elements for ATH434 Phase 3 program.
- Alignment reached with FDA on chemistry and manufacturing of ATH434.
- FDA endorsed plans for manufacture and testing of ATH434 for Phase 3 trial and commercialization.
- End-of-Phase 2 meeting with FDA remains on track for mid-2026.
- Substantial shareholder increased their holding in the company.
Financial Impact
No direct financial impact disclosed, but positive regulatory feedback supports readiness for Phase 3 initiation.
Risk Factors
- Potential delays in the Phase 3 program timeline.
- Regulatory hurdles in the End-of-Phase 2 meeting.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (PRNAF) — Batch item 1 | 0001437749-26-013364 |
| Document: athe20260427c_6k.htm | 0001437749-26-013362 |
| Document: 0001437749-26-013364-index-headers.html | 0001437749-26-013364 |
| Document: 0001437749-26-013364-index.html | 0001437749-26-013364 |
| Document: 0001437749-26-013364.txt | 0001437749-26-013364 |
| 6-K Filing (PRNAF) — Batch item 6 | 0001437749-26-013362 |
| Document: 0001437749-26-013362-index-headers.html | 0001437749-26-013364 |
| Document: 0001437749-26-013362-index.html | 0001437749-26-013364 |
| Document: 0001437749-26-013362.txt | 0001437749-26-013364 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 20w ago | 6-K | $0.0550 $0.0550 | · 0.00% | ▼ −1.39% | $0.2500 (+354.55%) |
Jun 4, 2026 20w ago | 6-K | $0.0550 $0.0550 | · 0.00% | ▲ +1.37% | $0.2500 (+354.55%) |
Jun 3, 2026 20w ago | 6-K | $0.0550 $0.0550 | · 0.00% | ▲ +1.00% | $0.2500 (+354.55%) |
May 29, 2026 21w ago | 6-K | $0.0550 $0.0550 | · 0.00% | ▲ +1.79% | $0.2500 (+354.55%) |
Apr 30, 2026 25w ago | 6-K | $0.0550 $0.0550 | · 0.00% | ▼ −5.23% | $0.2500 (+354.55%) |
Apr 29, 2026 25w ago | 6-K | $0.001100 $0.001100 | · 0.00% | ▼ −6.05% | $0.2500 (+22627.27%) |
Apr 27, 2026 26w ago | 6-K | $0.001100 $0.001100 | · 0.00% | ▼ −4.95% | $0.2500 (+22627.27%) |
Apr 22, 2026 26w ago | 6-K | $0.001100 $0.001100 | · 0.00% | ▼ −4.22% | $0.2500 (+22627.27%) |
Apr 21, 2026 27w ago | 6-K | $0.001100 $0.001100 | · 0.00% | ▼ −4.21% | $0.2500 (+22627.27%) |
Apr 20, 2026 27w ago | 6-K | $0.001100 $0.001100 | · 0.00% | ▼ −4.22% | $0.2500 (+22627.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers